Kim Mee-Seon, Lee Hyoun Wook, Jun Si-Youl, Lee Eun Hee
Department of Pathology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine Changwon, South Korea.
Department of Surgery, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine Changwon, South Korea.
Int J Clin Exp Pathol. 2015 Aug 1;8(8):8842-56. eCollection 2015.
Alpha B crystallin was characterized as a negative prognostic factor in breast cancer. BCL2 has an antiapoptotic role and sustains cell survival in vitro, ironically BCL2 expression has been associated with a good prognosis of breast cancer patients. To investigate the significance of alpha B crystallin and BCL2 expression in breast cancer and the relationship between these proteins, we performed immunohistochemical staining for both proteins in human breast cancer tissues. In the present study, overexpression of alpha B crystallin was observed more frequently in triple negative cancer (9/20, 45%) than in luminal type cancer (8/53, 15.1%, P=0.02161). BCL2 tended to be more highly expressed in luminal type cancer than in HER2 and triple negative cancer types (luminal: 36/53, 68%, HER2: 2/9, 22%, triple negative: 7/20 35%, P=0.008652). In multivariate analysis using ANCOVA, alpha B crystallin was related to short overall survival (P=0.017173). These findings suggest that alpha B crystallin is an independent prognostic factor of infiltrating ductal carcinoma. BCL2 was not associated with survival in multivariate analysis using ANCOVA. Thus, in our study BCL2 was not an independent prognostic indicator.
αB晶状体蛋白被认为是乳腺癌的一个负性预后因素。BCL2具有抗凋亡作用并能在体外维持细胞存活，具有讽刺意味的是，BCL2的表达与乳腺癌患者的良好预后相关。为了研究αB晶状体蛋白和BCL2表达在乳腺癌中的意义以及这两种蛋白之间的关系，我们对人乳腺癌组织中的这两种蛋白进行了免疫组化染色。在本研究中，αB晶状体蛋白的过表达在三阴性癌（9/20，45%）中比在管腔型癌（8/53，15.1%，P = 0.02161）中更频繁地被观察到。BCL2在管腔型癌中的表达往往高于HER2和三阴性癌类型（管腔型：36/53，68%；HER2：2/9，22%；三阴性：7/20，35%，P = 0.008652）。在使用协方差分析的多因素分析中，αB晶状体蛋白与总生存期缩短相关（P = 0.017173）。这些发现表明αB晶状体蛋白是浸润性导管癌的一个独立预后因素。在使用协方差分析的多因素分析中，BCL2与生存期无关。因此，在我们的研究中，BCL2不是一个独立的预后指标。
